QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burns, T. L Articles by Ineck, J. R Search for Related Content PubMed PubMed Citation Articles by Burns, T. L Articles by Ineck, J. R

PAIN MANAGEMENT

Cannabinoid Analgesia as a Potential New Therapeutic Option in the Treatment of Chronic Pain

at time of writing, Pharmacy Practice Resident, Creighton University Medical Center, Omaha, NE; now, Clinical Pharmacist, Mayo Clinic, Rochester, MN

Joseph R Ineck, PharmD

Clinical Specialist in Pain Management & Palliative Care; Assistant Professor, Department of Pharmacy Practice, School of Pharmacy and Health Professions, Creighton University

Reprints: Dr. Ineck, Department of Phamacy Practice, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, NE 68178-0401, fax 402/449-4879, jineck{at}creighton.edu

OBJECTIVE: To review the literature concerning the physiology of the endocannabinoid system, current drug development of cannabinoid agonists, and current clinical research on the use of cannabinoid agonists for analgesia.

DATA SOURCES: Articles were identified through a search of MEDLINE (1966-August 2005) using the key words cannabis, cannabinoid, cannabi^*, cannabidiol, nabilone, THC, pain, and analgesia. No search limits were included. Additional references were located through review of the bibliographies of the articles identified.

STUDY SELECTION AND DATA EXTRACTION: Studies of cannabinoid agonists for treatment of pain were selected and were not limited by pain type or etiology. Studies or reviews using animal models of pain were also included. Articles that related to the physiology and pharmacology of the endocannabinoid system were evaluated.

DATA SYNTHESIS: The discovery of cannabinoid receptors and endogenous ligands for these receptors has led to increased drug development of cannabinoid agonists. New cannabimimetic agents have been associated with fewer systemic adverse effects than delta-9-tetrahydrocannabinol, including recent development of cannabis medicinal extracts for sublingual use (approved in Canada), and have had promising results for analgesia in initial human trials. Several synthetic cannabinoids have also been studied in humans, including 2 cannabinoid agonists available on the international market.

CONCLUSIONS: Cannabinoids provide a potential approach to pain management with a novel therapeutic target and mechanism. Chronic pain often requires a polypharmaceutical approach to management, and cannabinoids are a potential addition to the arsenal of treatment options.

Key Words: analgesia, cannabinoids, chronic pain

Published Online, January 31, 2006. www.theannals.com, DOI 10.1345/aph.1G217

This article has been cited by other articles:

				M. J. Seamon, J. A. Fass, M. Maniscalco-Feichtl, and N. A. Abu-Shraie Medical marijuana and the developing role of the pharmacist Am. J. Health Syst. Pharm., May 15, 2007; 64(10): 1037 - 1044. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]